Gilead Sciences Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 18,000

Employees

  • Stock Symbol
  • GILD

Stock Symbol

  • Investments
  • 68

  • Share Price
  • $68.07
  • (As of Friday Closing)

Gilead Sciences General Information

Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Contact Information

Website
www.gilead.com
Formerly Known As
Oligogen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 333 Lakeside Drive
  • Foster City, CA 94404
  • United States
+1 (650) 000-0000

Gilead Sciences Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gilead Sciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$68.07 $68.65 $67.62 - $87.86 $84.9B 1.25B 7.38M $4.54

Gilead Sciences Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 118,987,854 118,987,854 127,215,834 113,029,788
Revenue 27,116,000 27,116,000 27,281,000 27,305,000
EBITDA 10,496,000 10,496,000 8,852,000 11,329,000
Net Income 5,665,000 5,665,000 4,592,000 6,225,000
Total Assets 62,125,000 62,125,000 63,171,000 67,952,000
Total Debt 24,987,000 24,987,000 25,230,000 26,695,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Gilead Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.

Request a free trial

Gilead Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portf
Drug Discovery
Foster City, CA
18,000 As of 2023
000.00
0000

000000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
000000000000000
Basel, Switzerland
00000 As of 0000
0000
000000000 0000

00000

te velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cu
0000000000000
Thousand Oaks, CA
00000 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gilead Sciences Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland 00000 0000 000000000 0000
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 000.00 000000000 000.00
AbbVie Corporation North Chicago, IL 00000 000.00 000000000 000.00
Bristol-Myers Squibb Private Debt Financed Princeton, NJ 00000 000.00 000000000 000.00
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY 00000 00.000 000000000000 00.000
You’re viewing 5 of 25 competitors. Get the full list »

Gilead Sciences Patents

Gilead Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240091351-A1 Focal ionizing radiation and cd47/sirpa disruption anticancer combination therapy Pending 21-Sep-2022 00000000000
US-20240083984-A1 Dosing and scheduling regimen for broadly neutralizing antibodies Pending 26-Aug-2022 00000000000
US-20240034724-A1 Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection Pending 01-Jul-2022 0000000000
US-20240043466-A1 Solid forms of a nucleoside analogue and uses thereof Pending 30-Jun-2022 000000000
US-20240051962-A1 Solid forms of a nucleoside analogue and uses thereof Pending 29-Jun-2022 C07D487/04
To view Gilead Sciences’s complete patent history, request access »

Gilead Sciences Executive Team (60)

Name Title Board Seat Contact Info
Daniel O'Day Chief Executive Officer, Chairman of the Board & Director
Andrew Dickinson Chief Financial Officer, Finance
Wim Eeraerts General Manager - Belgium & Luxemburg
Kevin Ho Member of Corporate Development Team, Corporate Strategy & Projects
Laura Quock Senior Director, Corporate Development
You’re viewing 5 of 60 executive team members. Get the full list »

Gilead Sciences Board Members (23)

Name Representing Role Since
Anthony Welters JD Self Board Member 000 0000
Daniel O'Day Gilead Sciences Chief Executive Officer, Chairman of the Board & Director 000 0000
Harish Manwani Self Board Member 000 0000
Jacqueline Barton Gilead Sciences Board Member 000 0000
Javier Rodriguez Self Board Member 000 0000
You’re viewing 5 of 23 board members. Get the full list »

Gilead Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gilead Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.

Request a free trial

Gilead Sciences Investments & Acquisitions (68)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Leap Therapeutics 11-Apr-2024 0000 0000 Biotechnology
CymaBay Therapeutics 22-Mar-2024 0000000000 00.00 Biotechnology 000000 0'
Arcus Biosciences 30-Jan-2024 0000 00000 Biotechnology 000000 00
Mego Afek 28-Dec-2023 000000000 0000 Therapeutic Devices
Hookipa Pharma 20-Dec-2023 PIPE 000.00 Biotechnology
You’re viewing 5 of 68 investments and acquisitions. Get the full list »

Gilead Sciences Subsidiaries (4)

Company Name Industry Location Founded
Kite Pharma Biotechnology Santa Monica, CA 2009
Myogen Pharmaceuticals Westminster, CO 0000
CymaBay Therapeutics Biotechnology Fremont, CA 0000
Immunomedics Drug Discovery Morris Plains, NJ 0000
To view Gilead Sciences’s complete subsidiaries history, request access »

Gilead Sciences ESG

Risk Overview

Risk Rating

Updated March, 30, 2024

22.45 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,173

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 909

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 401

Rank

00.00

Percentile

To view Gilead Sciences’s complete esg history, request access »

Gilead Sciences Exits (14)

Company Name Exit Date Exit Type Exit Size Status Buyers
Pardes Biosciences 27-Dec-2021 0000 0000 Completed
  • 4 buyers
Tango Therapeutics 10-Aug-2021 0000 00000 Completed
  • 18 buyers
Barinthus Biotherapeutics 17-Mar-2021 00000 00000 00 00000 Completed
  • 9 buyers
Tango Therapeutics 17-Aug-2020 00000 00000 00 0000 Completed
  • 5 buyers
Glympse Bio 15-Jul-2020 Later Stage VC 000.00 Completed
  • 13 buyers
You’re viewing 5 of 14 exits. Get the full list »

Gilead Sciences FAQs

  • When was Gilead Sciences founded?

    Gilead Sciences was founded in 1987.

  • Who is the founder of Gilead Sciences?

    Michael Riordan is the founder of Gilead Sciences.

  • Who is the CEO of Gilead Sciences?

    Daniel O'Day is the CEO of Gilead Sciences.

  • Where is Gilead Sciences headquartered?

    Gilead Sciences is headquartered in Foster City, CA.

  • What is the size of Gilead Sciences?

    Gilead Sciences has 18,000 total employees.

  • What industry is Gilead Sciences in?

    Gilead Sciences’s primary industry is Drug Discovery.

  • Is Gilead Sciences a private or public company?

    Gilead Sciences is a Public company.

  • What is Gilead Sciences’s stock symbol?

    The ticker symbol for Gilead Sciences is GILD.

  • What is the current stock price of Gilead Sciences?

    As of 12-Apr-2024 the stock price of Gilead Sciences is $68.07.

  • What is the current market cap of Gilead Sciences?

    The current market capitalization of Gilead Sciences is $84.9B.

  • What is Gilead Sciences’s current revenue?

    The trailing twelve month revenue for Gilead Sciences is $27.1B.

  • Who are Gilead Sciences’s competitors?

    Novartis, Amgen, AbbVie, Bristol-Myers Squibb, and Regeneron Pharmaceuticals are some of the 25 competitors of Gilead Sciences.

  • What is Gilead Sciences’s annual earnings per share (EPS)?

    Gilead Sciences’s EPS for 12 months was $4.54.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »